Publication:
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.

Simple item page
dc.contributor.authorMartínez-Cuadrón, David
dc.contributor.authorBoluda, Blanca
dc.contributor.authorMartínez, Pilar
dc.contributor.authorBergua, Juan
dc.contributor.authorRodríguez-Veiga, Rebeca
dc.contributor.authorEsteve, Jordi
dc.contributor.authorVives, Susana
dc.contributor.authorSerrano, Josefina
dc.contributor.authorVidriales, Belen
dc.contributor.authorSalamero, Olga
dc.contributor.authorCordón, Lourdes
dc.contributor.authorSempere, Amparo
dc.contributor.authorJiménez-Ubieto, Ana
dc.contributor.authorPrieto-Delgado, Julio
dc.contributor.authorDíaz-Beyá, Marina
dc.contributor.authorGarrido, Ana
dc.contributor.authorBenavente, Celina
dc.contributor.authorPérez-Simón, José Antonio
dc.contributor.authorMoscardó, Federico
dc.contributor.authorSanz, Miguel A
dc.contributor.authorMontesinos, Pau
dc.contributor.authorCETLAM and PETHEMA groups
dc.date.accessioned2023-01-25T10:04:18Z
dc.date.available2023-01-25T10:04:18Z
dc.date.issued2018
dc.description.abstractThe name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández in the original article.The original version of this article was revised: The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández.
dc.identifier.doi10.1007/s00277-018-3277-x
dc.identifier.essn1432-0584
dc.identifier.pmid29473097
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007%2Fs00277-018-3277-x.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12172
dc.issue.number5
dc.journal.titleAnnals of hematology
dc.journal.titleabbreviationAnn Hematol
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number923
dc.pubmedtypeJournal Article
dc.pubmedtypePublished Erratum
dc.rights.accessRightsopen access
dc.titleCorrection to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number97
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Reina Sofía
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía